Company Overview - NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease, addressing significant unmet medical needs with limited therapeutic options available [3][4] Compliance with Nasdaq - NeuroSense has regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price of $1.00 or more for at least 10 consecutive business days as of September 20, 2024, thus closing the prior bid price deficiency matter [1][2] Future Developments - The CEO of NeuroSense expressed optimism about advancing their treatment PrimeC, highlighting the positive momentum following Phase 2b trial results and the anticipation of initiating the Phase 3 trial in the US while continuing discussions with potential partners [3]
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule